Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Neurocrine Biosciences is a drug manufacturers-specialty & generic business based in the US. Neurocrine Biosciences shares (NBIX) are listed on the NASDAQ and all prices are listed in US Dollars. Neurocrine Biosciences employs 1,300 staff and has a trailing 12-month revenue of around $1.6 billion.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $91.22 |
|---|---|
| 52-week range | $88.38 - $129.29 |
| 50-day moving average | $98.99 |
| 200-day moving average | $107.48 |
| Wall St. target price | $124.67 |
| PE ratio | 144.7937 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.63 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $91.22 from 2023-05-26
| 1 week (2023-05-24) | -1.50% |
|---|---|
| 1 month (2023-05-01) | -12.31% |
| 3 months (2023-03-03) | -9.84% |
| 6 months (2022-12-01) | -27.78% |
| 1 year (2022-05-27) | -2.02% |
|---|---|
| 2 years (2021-05-28) | -5.20% |
| 3 years (2020-05-29) | 124.76 |
| 5 years (2018-05-31) | 96.26 |
Valuing Neurocrine Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Neurocrine Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
| Revenue TTM | $1.6 billion |
|---|---|
| Operating margin TTM | 17.24% |
| Gross profit TTM | $1 billion |
| Return on assets TTM | 7.65% |
| Return on equity TTM | 4.16% |
| Profit margin | 4% |
| Book value | $17.28 |
| Market capitalisation | $8.9 billion |
TTM: trailing 12 months
We're not expecting Neurocrine Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Neurocrine Biosciences's shares have ranged in value from as little as $88.38 up to $129.29. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neurocrine Biosciences's is 0.4877. This would suggest that Neurocrine Biosciences's shares are less volatile than average (for this exchange).
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia.
Access remote advice, planning and portfolio management from this established financial services company.
Steps to owning and managing ET, with 24-hour and historical pricing before you buy.
Steps to owning and managing UEC, with 24-hour and historical pricing before you buy.
Steps to owning and managing GROY, with 24-hour and historical pricing before you buy.
The best trading apps come with low fees and are easy to use.
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.